Literature DB >> 11322957

Duffy-null promoter heterozygosity reduces DARC expression and abrogates adhesion of the P. vivax ligand required for blood-stage infection.

P Michon1, I Woolley, E M Wood, W Kastens, P A Zimmerman, J H Adams.   

Abstract

The Duffy blood group antigen is an essential receptor for Plasmodium vivax entry into erythrocytes in a process mediated by the parasite ligand, the Duffy binding protein (DBP). Recently, individuals living in a malaria endemic region of Papua New Guinea were identified as heterozygous for a new allele conferring Duffy negativity, which results in 50% less Duffy antigen on their erythrocytes. We demonstrate that DBP adherence to erythrocytes is significantly reduced for erythrocytes from heterozygous individuals who carry one Duffy antigen negativity allele. These data provide evidence that emergence of this new allelic form of Duffy negativity is correlated with resistance against vivax malaria.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11322957     DOI: 10.1016/s0014-5793(01)02370-5

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  33 in total

1.  Shedding light on DARC: the role of the Duffy antigen/receptor for chemokines in inflammation, infection and malignancy.

Authors:  K Horne; Ian J Woolley
Journal:  Inflamm Res       Date:  2009-03-17       Impact factor: 4.575

Review 2.  Molecular basis of the Duffy blood group system.

Authors:  Gabriela Höher; Marilu Fiegenbaum; Silvana Almeida
Journal:  Blood Transfus       Date:  2017-01-30       Impact factor: 3.443

3.  Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodies.

Authors:  Francis B Ntumngia; Jesse Schloegel; Samantha J Barnes; Amy M McHenry; Sanjay Singh; Christopher L King; John H Adams
Journal:  Infect Immun       Date:  2012-01-03       Impact factor: 3.441

Review 4.  How malaria has affected the human genome and what human genetics can teach us about malaria.

Authors:  Dominic P Kwiatkowski
Journal:  Am J Hum Genet       Date:  2005-07-06       Impact factor: 11.025

5.  Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein.

Authors:  Francis B Ntumngia; John H Adams
Journal:  Clin Vaccine Immunol       Date:  2011-11-23

6.  Is there a genetic basis for health disparities in human immunodeficiency virus disease?

Authors:  Cheryl Winkler
Journal:  Mt Sinai J Med       Date:  2010 Mar-Apr

Review 7.  Red blood cell polymorphism and susceptibility to Plasmodium vivax.

Authors:  Peter A Zimmerman; Marcelo U Ferreira; Rosalind E Howes; Odile Mercereau-Puijalon
Journal:  Adv Parasitol       Date:  2013       Impact factor: 3.870

8.  Acquired antibody responses against Plasmodium vivax infection vary with host genotype for duffy antigen receptor for chemokines (DARC).

Authors:  Amanda Maestre; Carlos Muskus; Victoria Duque; Olga Agudelo; Pu Liu; Akihide Takagi; Francis B Ntumngia; John H Adams; Kim Lee Sim; Stephen L Hoffman; Giampietro Corradin; Ivan D Velez; Ruobing Wang
Journal:  PLoS One       Date:  2010-07-15       Impact factor: 3.240

9.  Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II.

Authors:  Francis B Ntumngia; Samantha J Barnes; Amy M McHenry; Miriam T George; Jesse Schloegel; John H Adams
Journal:  Clin Vaccine Immunol       Date:  2014-06-25

10.  Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II.

Authors:  Francis B Ntumngia; Jesse Schloegel; Amy M McHenry; Samantha J Barnes; Miriam T George; Sandra Kennedy; John H Adams
Journal:  Vaccine       Date:  2013-07-31       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.